Year 2022 / Volume 114 / Number 12
Editorial
New actors come into play against hepatitis delta

702-704

DOI: 10.17235/reed.2022.9050/2022

Mar Riveiro-Barciela, Adriana Palom, Maria Buti,

Abstract
Currently chronic hepatitis delta (CHD) represents the most severe form of chronic viral hepatitis. The risk of developing cirrhosis, hepatocellular carcinoma (HCC) and decompensated liver disease is 2-3 times greater in hepatitis delta virus (HDV) infection than in hepatitis B virus (HBV). For instance, in a study carried out in Italy including 299 CHD patients followed for 28 years, 82 (27%) developed cirrhosis, and among these, 46 (56%) developed HCC. The real number of subjects infected by HDV worldwide remains unknown due to the lack of information in many areas, though it has been suggested that the rate of HBsAg carriers co-infected by HDV may be situated between 4.5 and 18%.
Share Button
New comment
Comments
No comments for this article
References
1. Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. Journal of hepatology. 2021;74(5):1200-1211.
2. Farci P, Niro GA. Clinical features of hepatitis D. Seminars in liver disease. 2012;32(3):228-236.
3. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629-1638.
4. Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018.
5. Wedemever H, Yurdaydin C, Dalekos GN, et al. 72 week data of the HIDIT‑1 trial: A multicenter randomised study comparing peginterferon alpha‑2a plus adefovir vs. peginterferon alpha‑2a plus placebo vs. adefovir in chronic delta hepatitis. Journal of hepatology. 2007;46(Supplement 1):S4
6. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. The New England journal of medicine. 2011;364(4):322-331.
7. Palom A, Rodríguez-Tajes S, Navascués CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Alimentary pharmacology & therapeutics. 2020;51(1):158-166.
8. Palom A, Sopena S, Riveiro-Barciela M, et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. Alimentary pharmacology & therapeutics. 2021;54(4):462-469.
9. Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. Journal of hepatology. 2016;65(3):490-498.
10. Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. Journal of hepatology. 2018;68(Supplement 1):S3
11. Wedemeyer H, Schöneweis K, Bogomolov P, et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. Journal of hepatology. 2019;70(Suppl 1):e81.
12. Wedemeyer H, Aleman S, Andreone P, et al. Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study. Journal of hepatology. 2021;75(Suppl 2):S294.
13. Wedemeyer H, Aleman S, Brunetto M, et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study. Journal of hepatology. 2022;77(S1):S4.
14. Asselah T, Loureiro D, Le Gal F, et al. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life. Liver international : official journal of the International Association for the Study of the Liver. 2021;41(7):1509-1517.
15. Jachs M, Schwarz C, Panzer M, et al. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of A "real world" Study. Alimentary pharmacology & therapeutics. 2022.
16. Loglio A, Ferenci P, Uceda Renteria SC, et al. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. Journal of hepatology. 2022;76(2):464-469.
17. Fontaine H, Fougerou-Leurent C, Gordien E, et al. Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort. Journal of hepatology. 2022;77(S1):S72.
18. Einav S, Glenn JS. Prenylation inhibitors: a novel class of antiviral agents. The Journal of antimicrobial chemotherapy. 2003;52(6):883-886.
19. Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. The Lancet Infectious diseases. 2015;15(10):1167-1174.
20. Yurdaydin C, Keskin O, Kalkan C, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. Hepatology (Baltimore, Md). 2018;67(4):1224-1236.
21. Yurdaydin C, Keskin O, Yurdcu E, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology (Baltimore, Md). 2022;75(6):1551-1565.
22. Etzion O, Hamid S, Lurie Y, et al. End of Study Results from LIMT HDV Study: 36% Durable Virologic Response at 24 Weeks Post-Treatment with Pegylated Interferon Lambda Monotherapy in Patients with Chronic HDV Infection. Journal of hepatology. 2019;70(1):e32.
23. Bazinet M, Pantea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. The lancet Gastroenterology & hepatology. 2017;2(12):877-889.
Related articles

Editorial

Treatment of portal vein thrombosis in cirrhosis patients

DOI: 10.17235/reed.2023.9800/2023

Editorial

AKI-HRS, more than a name change for type-1 hepatorenal syndrome

DOI: 10.17235/reed.2023.9677/2023

Letter

Hepatitis B virus reactivation after ibrutinib treatment

DOI: 10.17235/reed.2023.9587/2023

Letter

Hemoperitoneum due to rupture of intra-abdominal varices

DOI: 10.17235/reed.2022.8937/2022

Letter

Cirrhotic pattern in advanced hepatic sarcoidosis

DOI: 10.17235/reed.2021.8446/2021

Digestive Diseases Image

Giant cystic hepatocarcinoma in the absence of cirrhosis

DOI: 10.17235/reed.2021.8313/2021

Review

Physical frailty in liver transplantation

DOI: 10.17235/reed.2020.7448/2020

Review

Risk stratification and treatment of primary biliary cholangitis

DOI: 10.17235/reed.2018.5662/2018

Citation tools
Riveiro-Barciela M, Palom A, Buti M. New actors come into play against hepatitis delta. 9050/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1284 visits.
This article has been downloaded 110 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 01/07/2022

Accepted: 31/07/2022

Online First: 31/08/2022

Published: 12/12/2022

Article Online First time: 61 days

Article editing time: 164 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology